Immunohistochemistry of DNA Mismatch Repair Enzyme MSH2 Is Not Correlated with Prognostic Data from Endometrial Carcinomas

被引：0
作者：
Schroeer, Andreas [1 ]
Koester, Frank [1 ]
Fischer, Dorothea [1 ]
Dubitscher, Ralph Martin [2 ]
Woll-Hermann, Astrid [2 ]
Diedrich, Klaus [1 ]
Friedrich, Michael [3 ]
Salehin, Darius [3 ]
机构：
[1] Med Univ Lubeck, Dept Gynecol & Obstet, D-23538 Lubeck, Germany
[2] Saarland Univ Hosp, Dept Gynecol & Obstet, D-66421 Homburg, Germany
[3] HELIOS Hosp Krefeld, Dept Gynecol & Obstet, D-47805 Krefeld, Germany
来源：
ANTICANCER RESEARCH | 2009年 / 29卷 / 11期
关键词：
Endometrial cancer; DNA mismatch repair; MSH2; immunohistochemistry; HUMAN MUT-S-HOMOLOGON-2; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; PROMOTER REGION; MUTS HOMOLOG; GENE HMSH2; EXPRESSION; P53; CISPLATIN; PROTEINS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: The human Mut-S-homolog-2 (MSH2) is part of the DNA mismatch repair system (MMR). Mutations in genes of the MMR are a predisposition to hereditary non-polyposis colorectal cancer (HNPCC). In women, MMR gene mutations may lead to primary endometrial cancer (EC). The important function of the MMR for the integrity of the DNA during replication makes it probable that the MMR might also be involved in the development and the course of sporadic carcinomas. Insufficient MMR activity or expression levels could be prognostic markers of the disease. Patients and Methods: Immunohistochemical analysis of MSH2 was performed in 86 tumor samples from patients with EC. Results: Compared to known tumor markers, namely estrogen and progesterone receptors, histopathological grading, TNM stage and FIGO classification, no significant correlation between MSH2 immunoreactivity and EC was found. Conclusion: MSH2 immunohistochemical analysis is not of prognostic value for endometrial carcinoma.
引用
收藏
页码：4833 / 4837
页数：5
相关论文
共 34 条
[11]   Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions [J].
Cooper, W. A. ;
Kohonen-Corish, M. R. J. ;
Chan, C. ;
Kwun, S. Y. ;
McCaughan, B. ;
Kennedy, C. ;
Sutherland, R. L. ;
Lee, C-S .
HISTOPATHOLOGY, 2008, 52 (05) :613-622
[12]   Cisplatin and adriamycin resistance are associated with MutL alpha and mismatch repair deficiency in an ovarian tumor cell line [J].
Drummond, JT ;
Anthoney, A ;
Brown, R ;
Modrich, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (33) :19645-19648
[13]  
Erdamar S, 2007, WORLD J GASTROENTERO, V13, P4437
[14]   Resistance to topoisomerase poisons due to loss of DNA mismatch repair [J].
Fedier, A ;
Schwarz, VA ;
Walt, H ;
Carpini, RD ;
Haller, U ;
Fink, D .
INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (04) :571-576
[15]   THE HUMAN MUTATOR GENE HOMOLOG MSH2 AND ITS ASSOCIATION WITH HEREDITARY NONPOLYPOSIS COLON-CANCER [J].
FISHEL, R ;
LESCOE, MK ;
RAO, MRS ;
COPELAND, NG ;
JENKINS, NA ;
GARBER, J ;
KANE, M ;
KOLODNER, R .
CELL, 1993, 75 (05) :1027-1038
[16]   Immunohistochemical analysis of DNA 'mismatch-repair' enzyme human Mut-S-Homologon-2 in ovarian carcinomas [J].
Friedrich, M ;
Villena-Heinsen, C ;
Meyberg, R ;
Woll-Hermann, A ;
Reitnauer, K ;
Schmidt, W ;
Tilgen, W ;
Reichrath, J .
HISTOCHEMICAL JOURNAL, 1999, 31 (11) :717-722
[17]  
Friedrich M, 1999, ANTICANCER RES, V19, P3349
[18]   Malignancies of the uterine corpus and immunoreactivity score of the DNA "mismatch-repair" enzyme human Mut-S-Homologon-2 [J].
Friedrich, M ;
Villena-Heinsen, C ;
Reitnauer, K ;
Schmidt, W ;
Tilgen, W ;
Reichrath, J .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1999, 47 (01) :113-118
[19]  
Friedrich M, 2000, EUR J GYNAECOL ONCOL, V21, P273
[20]   Selection of Endometrial Carcinomas for DNA Mismatch Repair Protein Immunohistochemistry Using Patient Age and Tumor Morphology Enhances Detection of Mismatch Repair Abnormalities [J].
Garg, Karuna ;
Leitao, Mario M., Jr. ;
Kauff, Noah D. ;
Hansen, Jessica ;
Kosarin, Kristi ;
Shia, Jinru ;
Soslow, Robert A. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2009, 33 (06) :925-933
1234